Gilead Sciences is a biopharmaceutical company that focuses on the research, development, and commercialization of innovative therapeutics to address significant unmet medical needs, particularly in the fields of antiviral therapies, oncology, and inflammation. The company is well-known for its advancements in treatments for diseases such as HIV, hepatitis C, and influenza, while also expanding its portfolio to include oncology products and therapies for other serious conditions. Gilead is committed to improving patient outcomes through its cutting-edge science and collaborative efforts, working to develop medicines that have both transformative efficacy and address critical health challenges on a global scale. Read More
Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) reported revenue ahead of Wall Street’s expectations in Q1 CY2026, with sales up 4.4% year on year to...
Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) reported Q1 CY2026 results topping the market’s revenue expectations, with sales up 4.4% year on year...
Gilead Sciences (NASDAQ: GILD) will release Q1 earnings on May 7, with analysts expecting $1.91 EPS and $6.92B revenue. Stock closed at $136.30 on April 29.
Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) will be reporting earnings this Thursday after market close. Here’s what you need to know. Gilead Sci...
While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor exec...
The Nasdaq 100 (^NDX) is known for housing some of the most innovative and fastest-growing companies in the market. But not every stock in the index is a win...
Though Gilead Sciences has underperformed relative to the SPX over the past year, Wall Street analysts maintain a bullish outlook on the stock’s prospects.
Gilead Sciences, Inc. (Nasdaq: GILD) today announced the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) submission for bictegravir 75 mg/lenacapavir 50 mg (BIC/LEN) – an investigational, once-daily single-tablet combination regimen for the treatment of HIV in adults who are virologically suppressed. The FDA has granted priority review of the application and assigned a Prescription Drug User Fee Act (PDUFA) action date of August 27, 2026.
Gilead Sciences, Inc. (Nasdaq: GILD) today announced the successful completion of its previously announced acquisition of Arcellx, Inc. (Nasdaq: ACLX). Under the terms of the transaction, Gilead acquired Arcellx for $115 per share in cash, plus one non‑transferable contingent value right (CVR) of $5 per share, representing a total implied equity value of approximately $7.8 billion at the time of closing.
Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence. With such vast footprints, however, finding new are...
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its first quarter 2026 financial results and guidance will be released on Thursday, May 7, 2026 after the market closes. At 4:30 p.m. Eastern Time that day, Gilead’s management will host a webcast to discuss the company’s first quarter 2026 financial results and provide a business update.
